Discuss 5-Amino-1MQ on glp1chat
Join the forum to discuss research with other members.
At a glance
In cell and animal studies, 5-Amino-1MQ blocks NNMT, an enzyme that processes vitamin B3-related molecules. Researchers use it to see how that change affects energy use and fat tissue. It is a small molecule, not a peptide.
NNMT is one of the cell's chemical processing tools. Blocking it can leave more of its starting materials available and shift how fat cells handle energy in experiments. That is why this compound appears in weight and metabolism research. The observed changes come mainly from laboratory and animal work, not from the familiar effects of a vitamin B3 supplement.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source discusses metabolic and body-composition findings from experimental models. These observations should be separated from demonstrated benefits in people.[8][9][2]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of 5-Amino-1MQ.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Subcutaneous Protocol (2 mL = 5 mg/mL)
| Phase | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Days 1–2 (Tolerance) | 2.5 mg (2500 mcg) | 50 units (0.50 mL) |
| Days 3+ (Standard) | 5 mg (5000 mcg) | 100 units (1.00 mL) |
| Alternative BID | 2.5 mg twice daily | 50 units (0.50 mL) × 2 |
Frequency: Inject once or twice daily subcutaneously. Due to the compound’s plasma half-life of approximately 3.8–6.9 hours[5], twice-daily (BID) dosing may provide more sustained NNMT inhibition. A single 10 mg vial provides 2–4 days of material at these doses.
Additional schedule context & duration
Concise summary of the subcutaneous regimen.
- Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels[1][2].
- Schedule: Daily subcutaneous injections; each 10 mg vial provides 2–4 days of material.
- Dose Range: 2.5–5 mg once or twice daily.
- Reconstitution: 2.0 mL per 10 mg vial (5 mg/mL) for accurate measurements.
- Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).
Suggested approach for the 10 mg vial format.
- Start: 2.5 mg once daily to assess tolerance.
- Target: 5 mg once daily or 2.5 mg twice daily (BID).
- Frequency: Once or twice per day (subcutaneous).
- Vial Duration: Single 10 mg vial lasts 2–4 days at standard doses.
- Timing: Morning administration preferred; BID dosing may be split AM/PM.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved—solution should be clear (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.
Storage Instructions
Proper storage preserves compound stability.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months[4].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.
- Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues.
- Do not refreeze reconstituted solution.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[6].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[12][13].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[7].
- Slow injection may minimize any stinging sensation associated with the compound.
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on protocol duration using the 10 mg vial format at 5 mg/day.
- 5-Amino-1MQ Vials (10 mg each):
- 1 week (5 mg/day = 35 mg total) → 4 vials
- 2 weeks (5 mg/day = 70 mg total) → 7 vials
- 4 weeks (5 mg/day = 140 mg total) → 14 vials
- Insulin Syringes (U-100, 1 mL):
- 1 week (once daily): 7 syringes
- 2 weeks (once daily): 14 syringes
- 4 weeks (once daily): 28 syringes
- Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 1 week (4 vials × 2.0 mL = 8 mL) → 1 × 10 mL bottle
- 2 weeks (7 vials × 2.0 mL = 14 mL) → 2 × 10 mL bottles
- 4 weeks (14 vials × 2.0 mL = 28 mL) → 3 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
- 1 week (once daily): 14 swabs
- 2 weeks (once daily): 28 swabs
- 4 weeks (once daily): 56 swabs → recommend 1 × 100-count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 2 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
Nature Medicine (2014) — Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Research publication
PMC (2024) — Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunctions (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Source document
Frontiers in Pharmacology (2024) — NNMT: a novel therapeutic target for metabolic syndrome (opens in a new tab)www.frontiersin.org
Back to overview ↑ - 04
Source document
Creative Peptides — Peptide stability and storage guidelines for lyophilized compounds (opens in a new tab)www.creative-peptides.com
Back to overview ↑ - 05
Research publication
PubMed (2021) — LC-MS/MS assay for 5-amino-1-methylquinolinium: pharmacokinetic and oral bioavailability study (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Research publication
PMC — Subcutaneous drug injection review: pharmacologic considerations (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
PMC (2022) — Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Source document
Swolverine — 5-Amino-1MQ mechanism, benefits, stacking and cycling guide (opens in a new tab)swolverine.com
Back to overview ↑ - 12
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 13
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)www.cdc.gov
Back to overview ↑ - 15
Research publication
PMC — NNMT: a bad actor in fat makes good in liver (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.